cyrilzakka/clinical-trials huggingface dataset:
Survey on the Current Status of IFD Diagnosis and Treatment by Intensive Care Physicians in Sichuan Province (IFS)

The goal of this survey is to learn about the current status of the diagnosis and treatment of invasive fungal infections among intensive care physicians in Sichuan Province (IFS). Its primary focus lies on answering the following questions: ①awareness and proficiency in diagnosis and treatment; ②the use of antifungal medications; ③the application of microbiological identification and diagnostic methods. We aim to analyze the problems and deficiencies that existed among intensive care physicians in order to provide a basis for the development of targeted training and intervention measures.


Eligibility Criteria:
Inclusion Criteria:

* Intensive care physicians in medical institutions at all levels in Sichuan Province

Exclusion Criteria:

* Exclude non-Sichuan physicians.
* Excluding physicians who are not engaged in intensive care unit.
Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study)

The aim of the present study is to evaluate the efficacy and safety of Jinlida granules in patients with inadequately controlled type-2 diabetes and dyslipidemia under life style intervention.


Eligibility Criteria:
Inclusion Criteria:

1. age of 20-70 years;
2. diagnosed with type 2 diabetes inadequately controlled under life style intervention with 3 months before screening;
3. HbA1c ≥6.5% and ≤10.0%, and fasting plasma glucose ≥7 and ≤13.3mmol/L at baseline;
4. diagnosed with dislipidemia with triglycerides\>150mg/dL (1.70mmol/L), and/or total cholesterol \>200mg/dL (5.16mmol/L), and/or LDL-c\>100mg/dL (2.58mmol/L)
5. body mass index (BMI): 20\<BMI\<40 kg/m2;

Exclusion Criteria:

1. moderate or severe liver dysfunction, abnormal renal function;
2. severe dysfunction of the heart;
3. histories of acute diabetic complications including diabetic ketoacidosis or hyperosmolar hyperglycemic non-ketotic coma within 3 months;
4. psychiatric disease or severe infection;
5. pregnancy or planned pregnancy;
6. use of any drug (including insulin) for treatment of diabetes or dyslipidemia within 3 months;
7. use of chronic (\>7 days) systemic glucocorticoid therapy within 8 weeks or receive growth hormone therapy within 6 months;
8. diagnosed with type 1 diabetes, or gestational diabetes, or other specific types of diabetes;
9. history of malignant tumor within 5 years.
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

In this multi-center study, the investigators plan to develop a simple blood-based test for early detection of Alzheimer's disease (AD). The test is based on a single injection of Pramlintide, an amylin analogue and FDA-approved drug currently used for treatment of diabetes. The investigative team has provided evidence in humans with full-blown AD and AD-relevant mouse models that a single injection of Pramlintide transiently renders the blood brain barrier (BBB) more permeable to Amyloidbeta (Aß) peptides, allowing their efflux from the brain compartment into the blood. This Aß efflux causes a corresponding transient elevation of blood levels of Aß, the magnitude of which the applicants believe is proportional to the brain amyloid load as determined by AV-45 PET. The measured difference in the level of plasma Aß taken just before and a short time after injection should reveal the magnitude of the transient increase in blood Aß levels. Supportive preliminary data comes from later stage (full-blown) AD patients with more in-depth background studies in Tg2576 and 5X Familial Alzheimer's Disease (FAD) mouse models. If successful for use as an early AD (i.e., at the Mild Cognitive Impairment \[MCI\] stage) biomarker, this could be a game-changer for both early AD diagnostics and clinical trials aimed at identifying and testing the efficacy of drugs useful for treatment of AD at early stages. If Pramlintide is effective in releasing mobile pools of Aß from the brain into the blood, this could also have some therapeutic potential, with the goal of reducing brain amyloid load.

Three groups of particpants will be studied: 1) amnestic MCI with or without positive AD imaging pathology, 2) probable AD with positive imaging AD pathology, and 3) controls who have normal cognition and do not have memory complaints.


Eligibility Criteria:
Inclusion Criteria:

* Current research subjects at the BU ADC, VA BHS, or IU ADC
* A consensus diagnosis of probable AD, amnestic MCI, or control
* BMI of 20-35
* Probable AD subjects must be confirmed for positive AD pathology in the CNS
* Probable AD subjects must have a designated research proxy signed before they became demented.

Exclusion Criteria:

* Diabetes mellitus
* Gastroparesis
* Use of insulin, pramlintide, other injectable anti-hyperglycemic agents, such as glucagon like peptide-1 (GLP-1), or oral anti-diabetic products
* Unexplained hypoglycemia (glucose ≤ 60 mg/dL) or hyperglycemia (glucose ≥ 126 mg/dL) pre-injection
* History of stroke
* Seizures or use of anti-seizure medications
* History of brain injury and loss of consciousness
* Diagnosed cerebral amyloid angiopathy (CAA)
* Infection within 1 month
Emergency Department Re-evaluation Software Pilot Study

This is a research study to determine a method in improving emergency department waiting room care by using new software program.

This is a pilot study to determine the effectiveness of an emergency department re-evaluation software, to improve patient flow through an emergency department. The end goal of the study is to provide proof of the efficacy of the software and provide data such that the software can be improved upon. The study will include ED waiting room patients. The study will involve interaction with the software on a tablet for patients and software on a desktop for providers. The providers utilizing the software will not be considered part of the study, but rather focusing on the outcomes of the patients using the software. Patients will be selected by the provider as available for re-evaluation. Each patient will then be randomized into either a control group (software not used) and a "study" group (software used). Data analysis will be performed in conjunction with clinical statisticians at our institution. The risks of this study are primarily derived from patient privacy concerns, which have been addressed in the risk section.

Eligibility Criteria:
Inclusion:

* Individuals that are 18 and older who have been identified with completed lab work.
* Their primary language must be English to follow the instructions of the study.
* Cognitively sound

Exclusion:

* Minors
* Emergency Severity Index (ESI) class 1 patients
* Individual who cannot legally give consent
* Pregnant patients
* Non-english speakers
Treatment of Infected Dialysis Catheters With Fiber Optic Ultraviolet Light

This study is a first-in-man clinical trial using fiber optically delivered ultraviolet light for reducing viable bacteria within indwelling tunneled dialysis catheters.


Eligibility Criteria:
Inclusion Criteria:

* Be at least 18 years of age
* Have the ability to provide informed consent
* Have an implanted dialysis catheter of one of the following models: Medcomp Titan 15.5F x 24 cm or Medcomp Titan 15.5F x 28 cm
* Positive blood culture drawn from the catheter

Exclusion Criteria:

* Previous inclusion in study
* Pregnant
An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 Infection

This multicenter, retrospective, observational study will evaluate the therapeutic effectiveness of a strategy of induction with Fuzeon (enfuvirtide) within an optimized regimen of antiretroviral drugs in patients with HIV-1 infection in routine clinical practice.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* HIV-1+ infection
* Patients with a viral load \> 50 copies/ml who have received induction treatment with Fuzeon in combination with antiretroviral treatment
* Naïve for Fuzeon at initiation of induction treatment
* Antiretroviral treatment of at least 12 months duration

Exclusion Criteria:

* Patients who did not receive Fuzeon treatment
Feasibility of Measuring Skin Carotenoid Level in an Asthma Clinic

The purpose of this study is to assess the use of a practical tool to objectively measure the fruit and vegetable intake in people with asthma.

After consenting to join the study, all participants enter a single cohort, cross-sectional study to assess pulmonary function, asthma control, carotenoid level, and diet intake.

Eligibility Criteria:
Inclusion Criteria:

* Pulmonary patients 18 years of age and older
* Confirmed diagnosis of asthma by a physician and confirmed by a pulmonary physician
* English speaking
* Access to the internet

Exclusion Criteria:

* Acute upper or lower respiratory infection
* Systemic corticosteroids
* Recent or current confirmed diagnosis of Covid-19
Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.

The purpose of this research is to assess the rotational stability of the AcrySof IQ Vivity Extended Vision Toric IOL and Refractive Visual outcome.

Assessment of the rotational stability and Refractive Visual Outcome of the AcrySof IQ Vivity Extended Vision Toric IOL at the end of surgery, post op 1 day, post op 1 week and post op 4 weeks. Participants in this research study are 45 years of age or older and have planned implantation in at least one eye.

Eligibility Criteria:
Inclusion Criteria:

* Subjects undergoing cataract extraction with intraocular lens implantation.
* Age: 45 years and older.
* Willing and able to comply with scheduled visits and other study procedures.
* Subjects who require an IOL power in the range of +15.0 D to +25.0 D.
* Subjects with regular corneal astigmatism that can be treated with T3-T5.
* Have good ocular health, with no pathology that compromises visual acuity (Outside of residual refractive error and cataract)
* Potential postoperative visual acuity of 0.2 logMAR/ETDRS (20/32 Snellen) or better in both eyes.

Exclusion Criteria:

* Glaucoma.
* Clinically significant corneal dystrophy.
* Previous corneal refractive surgery (i.e LASIK, PRK, RK)
* Pupil abnormalities.
* Concurrent infectious/non-infectious uveitis.
* History of chronic intraocular inflammation.
* Visually significant macular disease.
* History of retinal detachment.
Verification of the Correct Insertion of a Central Venous Catheter

The investigators propose a prospective diagnostic validity study in which the correct location of the central venous catheter will be verified by ultrasound and then verified by radiography in the same patient, without modifying the usual clinical practice criteria.


Eligibility Criteria:
Inclusion Criteria:

* Patients over 18 years of age in whom a decision is made to place a supradiaphragmatic central venous catheter.
* Patients who agree to participate in the study

Exclusion Criteria:

* Patients with devices that may interfere with the ultrasound images.
* Patients with poor ultrasound window
* Patients with superior vena cava syndrome
Spasticity Multidisciplinary Management : QoL and Physical Activity Measurement with Connected Health Devices (PEPS)

PEPS is a 18 months prospective bicentric study on 30 patients with spastic foot. The main objective is to evaluate the mean daily gait perimeter modifications mesured by connected watch, 6 months after spastic equinus foot surgery versus before this surgery. Investigator will lend a connected watch during the first consultation, and the patient will use it during 10 days in order to collect his mean daily gait perimeter. A lot of other tests will be realised in order to caracterize the clinical picture of each patient. After patients will be operated and all caracteristics of the surgery will be collected. Finally, at 6 months appointment, investigator will do the same analysis than first appointment in order to comparate the data for functional prognosis.

The study is proposed to eligible patients after a pluridisciplinar specialised appointment in the Neurosurgery ward, realised by a neurosurgeon, an orthopedist and a PRM physician. After spastic equinus foot diagnosis needed surgery et after patient's consent to the surgery, investigator will proposed to patient to participate at our study.

Before surgery, demographic datas, spasticity clinical datas, clinical examination (Ashworth and Penn scale), past treatments are collected. Other investigations are realised : FIM, NFAC, Rivermead mobility index, Lower extremity functional scale, SF36, EQ5D. Gait perimeter are collected by the connected watch, and also with a 10 meters test, the gait perimeter on flat and level ground which is unencumbered by any obstacles, Gaitrite evaluation. Patient will conserved the connected watch during all the study duration.

Peroperative datas are collected for each pateints with 3 times. First, before surgery, investigator collect joint range of motion under general anesthesia but without curarization. Second, during surgery, the surgical technique is described, with which nerves and which muscles are treated. Finally, after surgery, investigator will de novo collect joint ranges with the same clinical conditions.

At 6 months appointment, routine datas are collected (surgical complications, clinical examination) and also the notified investifations (FIM, NFAC ...), clinical investigations (Gaitrite, connected watch datas ...)

Eligibility Criteria:
Inclusion Criteria:

* Over 18 years old
* Walking patient
* Spastic foot surgery indication
* Consent form ok
* Patient with iOS or Android mobile phone

Exclusion Criteria:

* Previous spastic surgery
* Psychiatric disease
* Pregnancy
Sensory Motor Integration Training in Erb's Palsy Childern

The aim of the study is to Study effect of sensory motor integration training on ADL activities in children with Erb's palsy.

Thirty-two participants , their age ranged from two to six years for both genders (sixteen children treated with designed occupational therapy program group A and sixteen treated with designed occupational therapy program and sensory motor integration training group B )

Eligibility Criteria:
Inclusion Criteria:

1. Their ages will be ranged from 2 to 6 years in both sexes.
2. The infants with Erb's palsy (C5-C6).
3. Can follow verbal commend
4. Muscle tone within normal and muscle power within functional range.
5. Intact vision and hearing.

Exclusion Criteria:

1. Children undergoing surgical treatment.
2. Cognitive problem and cognitive anomalies.
3. Children with Erb's engram.
4. Complete sensory loss.
5. Shoulder subluxation or dislocation.
Study of Knee Replacements for Patellofemoral Osteoarthritis

This is a randomized comparison of PFA and TKR in treatment of isolated patellofemoral osteoarthritis.

Isolated patellofemoral osteoarthritis can be a disabling condition of the knee necessitating knee arthroplasty. It is debated whether total knee replacement or isolated patellofemoral replacement is the better treatment option. This randomized trial attempts to give a qualified answer to the debate by comparing clinical outcome (range of movement, stability, effusion, patellofemoral tracking, tenderness, stair climbing), patient self assessment scores (EQ-5D, Oxford Knee Score, KOOS, SF-36, AKS), complications (infections, revisions), longevity (survival analysis) and cost (direct and indirect) for the two implant types.

The Avon patellofemoral implant has been chosen, as this is the patellofemoral implant with the best documentation. The PFC Sigma CR total knee implant has been chosen as it a current standard implant and market leader.

Eligibility Criteria:
Inclusion Criteria:

* Isolated PF-OA

Exclusion Criteria:

* Medial or lateral OA
Neuromuscular Block Monitoring During Monitored Thyroidectomy

Titration of neuromuscular block (NMB) plays a key role in intraoperative recurrent laryngeal nerve monitoring during thyroid surgery. Aim to titrate sugammadex dose based on neuromuscular block degree as a surgeon friendly protocol with high intraoperative neuromonitoring (IONM) quality.


Eligibility Criteria:
Inclusion Criteria:

* elective monitored thyroidectomy

Exclusion Criteria:

* previous thyroid surgery
* preexisting vocal cord palsy
Low-dose Radiotherapy Combined With Conventional Radiotherapy After Immunotherapy Failure

Response was evaluated according to the Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics (iRECIST) : ORR-To evaluate the objective effective rate of LDRT combined with SFRT and immunotherapy in patients with malignant tumors after immunotherapy resistance without standard regimens. PFS-To evaluate the progression-free survival (PFS) of patients with advanced malignant tumors after LDRT combined with SFRT and immunotherapy without standard regimens after immunotherapy resistance.DCR-To evaluate the proportion of patients with optimal response to LDRT and SFRT combined with immunotherapy to achieve complete response, partial response, or disease control after no standard regimen was available for immunotherapy resistance.HRQoL, AE and sAE-Evaluation of health related quality of life and safety of post-LDRT combined with SFRT and immunotherapy in patients with malignant tumors. To evaluate the benefit of patients in this trial.


Eligibility Criteria:
Inclusion Criteria:

* 1. The patient understood, participated voluntarily and signed the informed consent

  2. Age 18-65

  3. Cytologically or histologically confirmed malignancy

  4. Complete clinical data

  5. The number of primary and regional metastatic lymph nodes and distant metastatic lesions was ≤10, and the number of organ metastases was ≤5.

  6. Patients with malignant tumors who are resistant to immunotherapy (the patient's disease progression is evaluated after 6-8 weeks of treatment without improvement of clinical symptoms), and no standard treatment options are available.

  7. Measurable primary lesions and regions

Exclusion Criteria:

* 1. Missing key patient data

  2. Refusing or not cooperating with the study

  3. Patients who have participated in other clinical studies/trials within 3 months

  4. Patients with brain metastases

  5. Patients with any conditions that the investigator judged to be ineligible for study participation

  6. Patients with uncontrolled severe medical diseases who cannot tolerate radiotherapy

  7. Past immune-related side effects (immune myocarditis, pneumonia, etc.)

  8. Previous history of radiation therapy
Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer

RATIONALE: Chemosensitizers may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug.

PURPOSE: Randomized phase III trial to study the effectiveness of chemosensitivity testing to assign treatment for patients with stage III or stage IV ovarian cancer who have undergone surgery.

OBJECTIVES: I. Determine whether the use of a chemosensitivity assay to assign treatment improves the time to progression and response rates of patients with stage III/IV ovarian cancer.

OUTLINE: This is a randomized study. Patients are stratified according to size of tumor after debulking surgery, stage, and Swiss Group for Clinical Cancer Research center where treatment is received. Within 14 days after patients undergo debulking surgery, they are randomized to one of two treatment arms. Arm I: Patients randomized to this arm receive one of six treatment regimens: Regimen A - cisplatin/cyclophosphamide Regimen B - cisplatin/cyclophosphamide/doxorubicin Regimen C - carboplatin Regimen D - carboplatin/cyclophosphamide Regimen E - cisplatin/paclitaxel Regimen F - carboplatin/paclitaxel Arm II: Patients who are randomized to this arm are assigned a treatment regimen based on a chemosensitivity assay of tumor specimens collected after debulking surgery. If no valid assay result is obtained, patients receive carboplatin/cyclophosphamide. Treatment is repeated every 3-4 weeks for a total of 6 courses. Up to 4 more courses may be administered if a partial response is demonstrated. Patients are followed every 3 months for the first 2 years and every 6 months thereafter.

PROJECTED ACCRUAL: Approximately 300 patients will be accrued for this study over 6 years.

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically/pathologically confirmed stage III and IV ovarian cancer Complete surgical staging and debulking including total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and biopsies of suspicious lesions (if feasible) required No low malignant potential histology without any invasive lesions in the peritoneum

PATIENT CHARACTERISTICS: Age: 80 and under Performance status: 0-3 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No disorder that would prevent the application of any protocol treatment

PRIOR CONCURRENT THERAPY: See Disease Characteristics
Ayahuasca Assisted Psychotherapy for Grief

The aim of this study is to compare the effectiveness of an ayahuasca-assisted constructivist therapy with constructivist therapy and no treatment to decrease the severity of grief. A secondary purpose is to assess the effectiveness to prevent Persistent Complex Bereavement Disorder and Prolonged Grief Disorder, and to assess potential changes in avoidance, meaning-making and self-clarity. Subjective effects and Acceptance promoting effects of psychedelic drug are assessed after ayahuasca administration. A non-randomized controlled trial is proposed with three arms involving an experimental group (ayahuasca in concert with psychotherapy) and two control groups (psychotherapy and no treatment) with pretest, posttest and 3 months follow-up.

Grief is a deep and intense sorrow caused by the loss of someone loved. Although every person could benefit from support, only a substantial minority of bereaved people experience severe, persistent and disabling grief (PCBD), requiring treatment one year after the death of a loved one. However, pharmacotherapy alone has not proven to be effective, and while psychological interventions for prolonged grief disorder may be efficacious, the clinical effectiveness is small (Hedges' g: 0.41-0.45). As far as we know, no bereavement prevention program has proven to be effective, and early interventions are discouraged. Thus, there are no effective resources for supporting the bereaved during the months following the death of a loved one, a need which peaks during the months following the death, when grief is most intense and the bereaved lives are at their highest level of risk.

Eligibility Criteria:
Inclusion Criteria:

* Experienced the loss of a first- degree relative not more than 12 months prior to enrollment as indicated by self-report.
* Scores up to 40 in the Texas Revised Inventory of Grief (TRIG).

Exclusion Criteria:

* Pregnant or breastfeeding women.
* Hypertension (systolic blood pressure above 140 mm, diastolic above 90 mm and heart rate above 100 bpm).
* History of psychotic disorder (Axis I-II of the DSM-V).
* Substance use disorder (except nicotine).
* Alcohol consumption greater than 40 g/day.
* Receiving psychological or self-help therapy during the study on a regular basis.
* Receiving regular pharmacological therapy for complicated grief during the study.
* Regular intake of any type of medication in the month preceding the study.
* Treatment with single doses of symptomatic medication during the study may be accepted (as long as it can be assumed that the ingested drug has been completely eliminated on the days of the ayahuasca administrations).